tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Genmab (GMAB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioNTech SE (BNTXResearch Report) and Genmab (GMABResearch Report) with bullish sentiments.

BioNTech SE (BNTX)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on BioNTech SE, with a price target of $366.00. The company’s shares closed last Friday at $176.57.

According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -23.8% and a 17.9% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Black Diamond Therapeutics, and Turning Point Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for BioNTech SE with a $276.36 average price target.

See today’s best-performing stocks on TipRanks >>

Genmab (GMAB)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab today and set a price target of $47.00. The company’s shares closed last Friday at $34.67.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -33.0% and a 15.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Oncternal Therapeutics, and Inovio Pharmaceuticals.

Currently, the analyst consensus on Genmab is a Hold with an average price target of $47.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed